Overview: Moraxella catarrhalis TestIntroduction: The Moraxella catarrhalis Test detects Moraxella catarrhalis, a bacteria causing respiratory or ear infections, helping guide antibiotic treatment for cough or ear pain. Affecting 1 in 1,000 people with respiratory infections, M. catarrhalis poses diagnostic challenges due to co-infections. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses culture/PCR for high accuracy, supporting bacteriology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: M. catarrhalis Detection Test, Respiratory Infection Assay.
FDA Status: Laboratory-developed test (LDT), meeting bacteriology standards for diagnostic reliability.
Historical Milestone: M. catarrhalis testing began in the 1980s with research by Doern, who identified its role in infections. PCR advancements in the 2000s by Cepheid improved detection, surpassing earlier culture methods.
Purpose: Detects M. catarrhalis presence to diagnose respiratory or ear infections, guides antibiotic therapy, and evaluates patients with cough, aiming to resolve symptoms.
Test Parameters: M. catarrhalis presence
Pretest Condition: Fresh swab or sputum required. Collect swab or sputum. Report history of respiratory issues.
Specimen: Nasopharyngeal Swab (sterile swab/transport medium, 1-2 swabs), Sputum (sterile container, 5-10 mL); Swab or sputum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document cough or ear pain. Include current medications or vaccination status.
Consent: Written consent required, detailing the test's purpose, infection risks (e.g., pneumonia), and sample collection risks.
Procedural Considerations: Uses culture/PCR to detect bacteria, requiring labs with incubators or thermal cyclers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Medications may alter growth, requiring correlation.
Clinical Significance: Positive result confirms M. catarrhalis infection, guiding therapy. Early treatment might prevent complications, while untreated cases lead to worsening. Negative results may require other tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Gram stain, culture, or PCR panel to confirm diagnosis.
Test Limitations: Specific to M. catarrhalis; correlation with symptoms needed. False negatives possible with low bacterial load.
References: CDC Guidelines, 2023; Journal of Clinical Microbiology, Doern GV, 2022.
